#LCSM Chat Topic 6/15: Patient Reported Outcomes (PROs)—more effective than some approved cancer drugs for advanced disease
With the proliferation of smartphones and personal tracking devices (such as Fitbits), technology has the means for cancer patients to provide feedback to their healthcare providers about their symptoms and side effects of treatment. Such feedback is called “patient reported outcomes,” or PROs. However, PROs are difficult to measure in a consistent manner, and thus far have not been incorporated into many cancer center clinics or clinical trials. But times are changing. One of the big news items to come out of the huge American Society of Clinical Oncology (ASCO) Annual Meeting… Read More
#LCSM Chat Topic 5/18: What’s PFS Got to Do with It?
For our chat on 5/18/17, starting at 8 PM Eastern, 5 PM Pacific, we’ll cover several key trial results and the potential implications of them. While each has the potential to be practice changing, all three have the primary endpoint of progression-free survival (PFS) but, to our knowledge, don’t necessarily improve overall survival (OS). It is interesting that the differences between the settings and trial designs have led many lung cancer experts to favor adoption of some of these results but not necessarily others. But what do patients and caregivers think of… Read More
#LCSM Chat Topic 5/4 — The PDQ on MTBs: Why are multidisciplinary tumor boards important in #lungcancer?
Lung cancer is a complicated disease. Diagnosing and treating complex cases can require skills that cross a variety of medical specialties. Larger medical centers and hospitals may decide to discuss complex cases in tumor boards that include physicians that represent a variety of medical specialties. Our May 4, 2017, #LCSM Chat (at 8pm Eastern, 5pm Pacific) will focus on defining what a multidisciplinary tumor board (MTB) does, who is involved, and why MTB are important in the treatment of lung cancer. The National Cancer Institute defines a tumor board review as: A… Read More
#LCSM 
You must be logged in to post a comment.